- Home
- AVNS vs GHRS Comparison
AVNS vs GHRS Comparison
Compare AVNS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNS | GHRS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 947.2M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVNS | GHRS |
|---|---|---|
| Price | $24.80 | $21.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 2.0M | 264.3K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $225.41 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $9.52 |
| 52 Week High | $24.81 | $24.66 |
Technical Indicators
Market Signals| Indicator | AVNS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 90.70 | 61.80 |
| Support Level | $12.75 | $12.41 |
| Resistance Level | N/A | $24.66 |
| Average True Range (ATR) | 0.07 | 1.41 |
| MACD | -0.33 | 0.03 |
| Stochastic Oscillator | 64.52 | 65.78 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.